PCOS and Insulin Resistance

From a Western biomedical view, PCOS and insulin resistance are interlocked through endocrine and metabolic feedback loops. Insulin resistance in muscle and liver drives compensatory hyperinsulinemia, which acts directly on ovarian theca cells (and via IGF‑1 receptor cross‑talk) to upregulate androgen synthesis. In the liver, insulin suppresses SHBG, raising free testosterone and amplifying clinical hyperandrogenism. Androgens in turn favor visceral adiposity and worsen insulin sensitivity, establishing a self‑reinforcing cycle. Epidemiologically, insulin resistance spans 50–80% of PCOS, including lean phenotypes, and confers elevated risks of impaired glucose tolerance, type 2 diabetes, gestational diabetes, NAFLD, obstructive sleep apnea, and cardiometabolic abnormalities. Guidelines recommend screening for dysglycemia at PCOS diagnosis—preferably using a 75‑g oral glucose tolerance test—and every 1–3 years thereafter, alongside lipid, blood pressure, and liver fat assessment. Management addresses both symptom control and root metabolic dysfunction: structured lifestyle intervention (nutrition quality, calorie deficit when indicated, aerobic and resistance training, sleep optimization) yields meaningful improvements in ovulation and insulin sensitivity with as little as 5–10% weight loss. Pharmacotherapies include metformin for metabolic indications and cycle regulation; GLP‑1 receptor agonists for individuals with obesity and metabolic complications (off‑label in PCOS) can achieve substantial weight loss and may restore menses. Inositol supplements offer a low‑risk adjunct with moderate evidence; thiazolidinediones remain effective but second‑line due to adverse effects. Preconception planning is crucial to mitigate GDM risk, and agents used for weight loss (e.g., GLP‑1 RAs) should be discontinued well before attempted conception.

Eastern traditions frame PCOS and insulin resistance as manifestations of internal stagnation and deficiency. In TCM, phlegm‑damp accumulation and liver qi stagnation obstruct the Chong–Ren channels, while kidney deficiency underlies reproductive dysregulation. These concepts map functionally onto central adiposity, low‑grade inflammation, and neuroendocrine imbalance. Treatment aims to transform damp/phlegm, move qi, and tonify kidney/liver systems through individualized herbal prescriptions and acupuncture. Acupuncture protocols (often including SP6, ST36, CV3/4, PC6, and Zigong, with electroacupuncture) have shown modest improvements in insulin sensitivity and ovulatory function in small trials, possibly via autonomic modulation and myokine/endothelial effects. Herbal strategies may include berberine‑containing Coptis for ‘sugar stagnation,’ combinations to resolve phlegm and stasis, and formulas to support deficiency patterns; Ayurveda emphasizes Kapha‑pacifying diet, digestive fire (agni) restoration, and herbs like Gymnema and Shatavari. Mind–body practices (yoga, pranayama, meditation) can reduce stress reactivity and improve insulin action, with early RCTs suggesting benefits in adolescents and adults with PCOS. Evidence quality varies: while traditional frameworks provide a holistic lens and individualized care, high‑quality randomized trials remain limited and heterogeneous. As integrative care, these modalities are best layered atop guideline‑directed lifestyle and metabolic therapy, with careful attention to herb–drug interactions, quality control, and pregnancy planning.